up to 17 Months
Male or Female
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.
For further information about this study or to express your interest in this study, please fill out and submit this form.
This setting allows you to view available services and providers associated with your preferred location. You can change this setting at any time.
Cookies are required to view location-specific content.
We’ve developed a new tool on our website allowing you to see content most relevant to you and your preferred location. It’s our way of making the information you need, more personalized.
You’ll find this feature labeled “Set My Location” throughout the website. Most often, you’ll see it in the top left corner of every page.
You’ll also find a feature that allows you to set your location temporarily, as seen below.